OneHP™ by Aragen
One Platform. Ultra-High Containment.
From milligram discovery to multi-kilogram cGMP supply — high-potency payloads, linkers and bioconjugation, without the molecule ever leaving the facility.
Every handoff costs months — and momentum
High-potency molecules are now mainstream science: nearly 65% of oncology candidates in development are highly potent, and the global HPAPI market is growing. Yet most programs still move between three separate partners — discovery chemistry, process development, and GMP supply — re-qualifying containment and re-validating methods at every transfer. Add ADC ambitions, and few sites even qualify below the containment thresholds these molecules demand.
One partner. One containment standard. One quality system.
OneHP unifies discovery, development, analytical and cGMP manufacturing on a single integrated platform — so your high-potency molecule advances without ever changing hands.
Platform at a Glance
| Stage | Scale | Explore (Links) |
|---|---|---|
| Discovery chemistry | Up to 10gm | OneHP™ Discovery → |
| Non-GMP process development & scale-up | Up to 500gm | OneHP™ Development & Manufacturing → |
| cGMP manufacturing | 500gm to 5kg per batch; ~500–600kg annual capacity | OneHP™ Development & Manufacturing → |
Facility & Containment
- ~15,000 sq ft, purpose-built OEB-6 facility in Hyderabad, India
- Ultra-high containment: potent-compound handling systems with five levels of cascading protection, supporting occupational exposure limits (OELs) up to 10 ng/m³
- SafeBridge-qualified systems and operating procedures
Built for What’s Next: ADCs and Bioconjugation
Antibody-drug conjugates (ADCs) are among the fastest-growing therapeutic modalities, driving demand for integrated expertise across highly potent chemistry, biologics and conjugation.
OneHP™ already delivers the linker-payload chemistry that powers ADC programs, and is expanding to provide end-to-end bioconjugation and peptide-drug conjugate (PDC) capabilities at discovery scale.
By combining linker-payload synthesis, antibody and protein production, chemical and enzymatic conjugation, and advanced analytical characterization in a single high-containment environment, OneHP™ enables seamless development of ADCs, PDCs and next-generation conjugates — including novel payloads and emerging targeted delivery modalities. The entire high-potency-to-conjugate journey, under one roof.
Outcomes That Matter to Your Program
Reduce Risk
One integrated partner from linker-payload design through conjugation and GMP supply — no vendor handoffs, no revalidation cycles, no re-onboarding of a new team at each stage.
Ensure Continuity
Experienced scientists guide payload selection, linker design and route strategy from day one — so scalability and containment are engineered in, not discovered late.
Accelerate Timelines
Knowledge follows your molecule. The same platform that synthesizes your first milligrams characterizes your conjugate and manufactures your kilograms.
